Late last week, on December 9, the FDA approved<\/a> the Emergency Use Authorization (EUA) for the Pfizer COVID-19 vaccine, \u201cauthorizing the use of a single booster dose for administration to individuals 16 and 17 years of age.\u201d The booster is to be given at least 6 months after vaccination.<\/p>\n […] The Pfizer vaccine is particularly dangerous for young men aged 16-17. As we observed back in October<\/a>, teenage boys are especially at risk for heart problems \u2013 like myocarditis \u2013 after getting the Pfizer vaccine:<\/p>\n \u201cBoys between 16 and 19 years of age had the highest incidence of myocarditis after the second dose . . . The risk of heart problems in boys of that age was about nine times higher than in unvaccinated boys of the same age.\u201d – New York Times.<\/a><\/i><\/p>\n The risk of myocarditis for boys 16 \u2013 19 years old is higher after the Pfizer second dose. What happens after the third dose??<\/p>\n That\u2019s a good question.<\/p>\n One would rightly assume that the third dose might present more danger of heart problems than the second dose. But FDA doesn\u2019t have the answer to this question. And why doesn\u2019t it have the answer?<\/p>\n Because the FDA didn\u2019t look.<\/p>\n Because the FDA conducted ZERO tests in this age bracket before approving the latest Pfizer booster for this age bracket.<\/p>\n